Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law

Intellectual Property Law

: Orange Book Blog: At the Intersection of Patent Law and FDA Law

CBI "Paragraph IV Disputes" Conference, Philadelphia, October 15-16

By Aaron Barkoff

On October 15-16 in Philadelphia, the Center for Business Intelligence will hold a conference entitled "Pharmaceutical Congress on Paragraph IV Disputes:  Navigating Regulations and Enforcement Trends to Increase Preparedness and Optimize Paragraph IV Strategies."

CBI provides its top five reasons to attend:

• To hear the FTC's stance on antitrust and acceptable settlement strategies
• To learn to optimize cost savings in e-discovery
• To assess ANDA litigation after KSR
• To understand the "earlier of" - "later of" maze in forfeiture provisions
• To conduct an in-depth analysis of recent paragraph IV developments and their implications on industry

The conference will begin with a workshop, "Assess Litigation Strategies to Proactively Plan for Paragraph IV Disputes," on October 15 from 8:30 am to noon.

The main agenda then includes numerous talks that look interesting:

• "Strategies to Optimize Patent Lifecycle from Drafting to Maturity"
• "Preparing for Paragraph IV Challenges -- Generic Pre-suit Strategies"
• "Best Practices in E-Discovery -- Overcoming Obstacles, Controlling Costs and Maximizing Benefits"
• "The KSR Decision and ANDA Litigation"
• "Implications of Recent Developments and Trends in Litigating Paragraph IV Disputes" (I'll be speaking on this topic as one of the panelists)
• "Citizen Petitions and Their Impact on Generic Entry"
• "Interpreting Forfeiture Provisions -- An Analysis of Recent Cases to Increase Preparedness and Improve Product Strategy"
• "The FTC, Antitrust Law and Settling Paragraph IV Litigation," presented by Markus Meier, Assistant Director, FTC

For more information or to register, please visit the conference website.

Orange Book Blog readers can save $400 by using registration code SAQ782.

Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on September 27, 2008 (boomark / email).